

Mendelian randomization with time-varying exposures

Challenges in timing, estimation and interpretation



Joy Shi, PhD

Instructor of Epidemiology
CAUSAL and Department of Epidemiology
Harvard T.H. Chan School of Public Health



Disclosures

This research was supported by the U.S. Department of Veterans Affairs (VA) Office of Research and Development (ORD) Cooperative Studies Program (CSP) Epidemiology Center at the VA Boston Healthcare System through CSP #2032, by resources and the use of facilities at the VA Boston Healthcare System and VA Informatics and Computing Infrastructure (VINCI) (VA HSR RES 13-457).

The VA CAUSAL Methods Core is a collaboration between the Massachusetts Veterans Epidemiology, Research, and Information Center (MAVERIC) Division of Population Health and Data Sciences and the CAUSALab at the Harvard T.H. Chan School of Public Health.



Overview



Mendelian randomization (MR) as an application of instrumental variable (IV) analysis and its limitations



Causal interpretations of MR estimates and their assumptions



Methods to incorporate repeated measures of an exposure in MR analyses



An application of structural models in a MR study and current works in progress

3

Instrumental variable methods for causal inference


Three broad classes of causal inference methods:

1. Confounding adjustment approaches
2. Frontdoor criterion
3. Instrumental variable (IV) methods

For IV methods, need a variable (i.e., an instrument, Z) that meets three conditions:

1. Relevance

Associated with exposure



2. Exclusion restriction

Does not affect outcome except through potential effect on exposure


3. Independence

No common causes (or other sources of lack of exchangeability) with outcome

4

Mendelian randomization (MR) as an application of IV

- Increasingly popular application of instrumental variable analysis
- Genetic variants are used as proposed instruments
- Leverage genetic data to estimate the effect of a non-genetic exposure on an outcome



Z: genetic variant(s) related to LDL cholesterol

A: LDL cholesterol

Y: coronary artery disease

5

The appeal of MR studies



Identify causal effects even with unmeasured confounding



“Natural analogue” of a randomized controlled trial




Estimate the long-term (“lifetime”) effects of exposures

6


MR studies are generally concerned with the effects of time-varying exposures

- Examples: alcohol intake, blood pressure, LDL cholesterol, BMI, sleep duration, smoking
- Our IV DAG should reflect the fact that the exposure can change over time
- Time zero ($k = 0$) is at conception (when genes are assigned)

Time-fixed exposure



Time-varying exposure




However, most MR studies ignore the time-varying nature of the exposure.

Why?

- Most biobanks only measure phenotypes at one time point
- Conventional IV methods (e.g., Wald estimator, two-stage least squares) weren't designed for time-varying exposures

How are most MR studies conducted in practice?

- ✗ A single measurement of the exposure is considered in the analysis
- ✗ The timing of this exposure measurement varies across individuals (e.g., for some, it's at $k = 40$, for others at $k = 45$, etc.)



- ✗ MR estimate is interpreted as the “lifetime effect” of the exposure on the outcome


How can we do better with MR?

- ✗ Define the types of causal estimands that can be targeted using Mendelian randomization
- ✗ Describe what additional assumptions are needed (if any) to identify these causal estimands using Mendelian randomization
- ✗ Propose methods to account for time-varying exposures in IV analyses

1

Causal estimands in Mendelian randomization studies and their assumptions


What types of causal estimands can we target?



The exclusion restriction assumption for a point effect

$$E[Y^{a_m}] - E[Y^{a'_m}]$$

Recall our DAG for a time-varying exposure:



To estimate the point effect, Z must meet the three instrumental conditions for only A_m as the exposure


- ✗ Exclusion restriction assumption states “instrument does not affect outcome except through exposure”
- ✗ The only paths from Z to Y must go through A_m
- ✗ Presence of other exposure time points may violate this condition, e.g.

13

The exclusion restriction assumption for a point effect

$$E[Y^{a_m}] - E[Y^{a'_m}]$$

Recall our DAG for a time-varying exposure:



To estimate the point effect, Z must meet the three instrumental conditions for only A_m as the exposure


- ✗ Exclusion restriction assumption states “instrument does not affect outcome except through exposure”
- ✗ The only paths from Z to Y must go through A_m
- ✗ Presence of other exposure time points may violate this condition, e.g.
 - Z affects A_0 , and A_0 affects Y

14

The exclusion restriction assumption for a point effect

$$E[Y^{a_m}] - E[Y^{a'_m}]$$

Recall our DAG for a time-varying exposure:



To estimate the point effect, Z must meet the three instrumental conditions for only A_m as the exposure

- ✗ Exclusion restriction assumption states “instrument does not affect outcome except through exposure”
- ✗ The only paths from Z to Y must go through A_m
- ✗ Presence of other exposure time points may violate this condition, e.g.
 - Z affects A_0 , and A_0 affects Y
 - Z affects A_0 , A_0 affects another exposure time point (A_k), and A_k affects Y

15

The exclusion restriction assumption for a point effect

For the **exclusion restriction** assumption to hold, need all exposure time points other than A_m to be

- ✗ Unaffected by the instrument Z ; or
- ✗ Have no effect on the outcome Y not through A_m

But...


- ✗ Genetic variants often have long-term effects on the exposure
- ✗ Critical windows of exposure can span years or decades for some outcomes

In general, wouldn't expect the exclusion restriction assumption to hold when identifying the point effects in MR studies.

16

The exclusion restriction assumption for a period effect

$$E[Y^{a_{m-p}, \dots, a_{m-1}, a_m}] - E[Y^{a'_{m-p}, \dots, a'_{m-1}, a'_m}]$$



The **exclusion restriction** assumption must hold for the exposure during the time period $[m-p, \dots, m]$, i.e., all exposure time points other than $(A_{m-p}, \dots, A_{m-1}, A_m)$ need to


- ✗ Be unaffected by the instrument Z ; or
- ✗ Have no effect on the outcome Y not through $(A_{m-p}, \dots, A_{m-1}, A_m)$

With a longer period, the number of arrows that need to be removed decreases.

17

The exclusion restriction assumption for a lifetime effect

$$E[Y^{\bar{a}_k}] - E[Y^{\bar{a}'_k}]$$



- ✗ Can consider the lifetime effect as a type of period effect in which the period spans from time 0 (i.e., at conception) until time k (i.e., the development of the outcome)
- ✗ No violation of the exclusion restriction assumption through exposure time points (because we are intervening on all exposure time points)


18

Additional assumptions for the period/lifetime effect

- ✖ The IV conditions (and homogeneity/monotonicity) may not be sufficient for identifying the period effect in MR studies
- ✖ Additional assumptions may be needed
 - The types of assumptions will depend on the number of exposure measurements that are considered in the IV analysis
 - The number of exposure measurements also affects the types of period effects that can be identified

19

Identification of the period/lifetime effect with the exposure measured at one time point



Can identify the effects of shifting the whole exposure trajectory during the period (A_{m-p}, \dots, A_m) by one unit:

$$E[Y^{a_{m-p}+1, \dots, a_{m-1}+1, a_m+1}] - E[Y^{a_{m-p}, \dots, a_{m-1}, a_m}]$$


The magnitude of the association between the instrument and the exposure must stay constant during this period.

"If the relationship between $[Z]$ and A changes over time, it cannot be adequately summarized by measuring it at 1 time point."

(Labrecque and Swanson, AJE 2018)

20

Identification of the period/lifetime effect with the exposure measured at **all** relevant time points




- Need multiple instruments with variation in their associations with the exposure association to disentangle effects of the exposure between time points
- Regardless, can identify the overall effect of shifting the exposure trajectory

Can identify controlled direct effects of each time point, e.g.

- What if we increase earlier exposures but keep later exposures constant?
- What if we decrease early exposures but increase later exposures?

21

Identification of the period/lifetime effect with the exposure measured at a **subset** of all time points



- $Z-A_t$ association is constant from one measured exposure time point to the next to estimate the effect during that interval
- With variation in the instrument-exposure relationship, can identify controlled direct effects of each measured interval

22

2

Instrumental variable methods for time-varying exposures



Structural models for time-fixed outcomes

- Originally proposed to estimate the effects of time-varying exposures while adjusting for time-varying confounders
- Can be adapted for IV analyses but rarely used in practice
- Structural mean models are models for the **causal effect**
- For example, for a period effect:

$$E[Y^{a_{m-p}, \dots, a_{m-1}, a_m} - Y^0 | A_{m-p}, \dots, A_m, Z] = \gamma(A_{m-p}, \dots, A_m; \psi)$$

Model the period
effect of interest...

...conditional on the
exposures and the
instruments...

...as some function
(γ) of the exposures,
indexed by ψ ...

...where ψ represents the
estimate for the causal
effect(s) of interest

Structural models for time-fixed outcomes

- Originally proposed to estimate the effects of time-varying exposures while adjusting for time-varying confounders
- Can be adapted for IV analyses but rarely used in practice
- Structural mean models are models for the **causal effect**
- For example, for a period effect:

$$E[Y^{a_{m-p}, \dots, a_{m-1}, a_m} - Y^0 | A_{m-p}, \dots, A_m, Z] = \psi_1 A_{m-p} + \dots + \psi_p A_{m-1} + \psi_p A_m$$

ψ_1 represents effect of increasing A_{m-p} by one unit, holding A_{m-p+1}, \dots, A_m constant

25

Structural models for time-fixed outcomes

- Originally proposed to estimate the effects of time-varying exposures while adjusting for time-varying confounders
- Can be adapted for IV analyses but rarely used in practice
- Structural mean models are models for the **causal effect**
- For example, for a period effect:

$$E[Y^{a_{m-p}, \dots, a_{m-1}, a_m} - Y^0 | A_{m-p}, \dots, A_m, Z] = \psi_1 A_{m-p} + \dots + \psi_p A_{m-1} + \psi_p A_m$$

Because of our homogeneity assumption, this model cannot be dependent on Z (i.e. no effect modification by Z)

26

G-estimation

Each structural model corresponds to an estimating equation that is a function of ψ^* :

$$U(\psi^*; Z_i) = H_i(\psi^*)(Z_i - E(Z))$$

Note: we use ψ^* to represent “proposed” values of ψ

When ψ^* is equal to its true value (i.e. ψ), then the estimating equation (across all individuals i) will be equal to zero:


$$E[U(\psi; Z_i)] = 0$$

- ✗ For **additive structural mean models** (i.e. with continuous outcomes), there is a closed form solution to solve for ψ
- ✗ For **multiplicative structural mean models**, need to use a search algorithm (e.g. Newton Raphson) to solve for ψ

27

Structural models for failure time outcomes

We can also use structural models to model a failure-time outcome:



where Y_{k+1} is an indicator (1: yes, 0: no) for developing the outcome by the end of the period k

Here, we indicate a time-fixed instrument (e.g., in Mendelian randomization studies) but we could also have a time-varying instrument.

28

Structural nested cumulative failure time models (SNCFTMs)

$$\exp[\gamma_k(\bar{A}_m; \psi)] = \begin{cases} \frac{E[Y_k^{\bar{A}_m, 0} | \bar{A}_m, Z, Y_m = 0]}{E[Y_k^{\bar{A}_{m-1}, 0} | \bar{A}_m, Z, Y_m = 0]} & \text{if } Y_m = 0 \\ 1 & \text{if } Y_m = 1 \end{cases}$$

- Models the ratio of two counterfactual cumulative risks at time k under treatment strategies that differ only at time m for each time $m < k$
 - i.e., the conditional effect of a “blip” of treatment at time m on outcome at time k
- $\gamma_k(\bar{A}_m; \psi)$ is a blip function that is a function of treatment history through m , index by the parameter ψ
- The blip function cannot be a function of Z
- Example of a blip function: $\gamma_k(\bar{A}_m; \psi) = \psi A_m$

29

G-estimation of SNCFTMs

Solve the corresponding estimating equation

$$E[U(\psi; Z)] = 0$$

where

$$U(\psi; Z) = \sum_{m=0}^K (1 - Y_m) \sum_{k=m+1}^{K+1} (Z - E[Z | Y_m = 0]) H_{m,k}(\psi)$$

$$H_{m,k}(\psi) = \begin{cases} Y_k \exp\left(-\sum_{j=m}^{k-1} \gamma_j(\bar{A}_j; \psi)\right) & \text{if } Y_m = 0 \\ 1 & \text{if } Y_m = 1 \end{cases}$$

No closed form solution, so we use create a quadratic form of the estimating equation and use a search algorithm that finds the minimum (i.e., where $\psi = 0$) of this equation

30

Blipping down/up to obtain marginal counterfactual risks

- Our g-estimate $\hat{\psi}$ can be difficult to interpret (depending on the blip function)
- Can be used to calculate marginal counterfactual risks under a given treatment strategy

Blipping down:

- Estimate $E[Y_k^0]$
- "Remove" the effect (ψ) of each subject's nonzero treatments from the end of the study to the beginning of the study

Blipping up:

- Estimate $E[Y_k^g]$
- "Adding" the effect of treatment to $E[Y_k^0]$ from the beginning of the study period to the end of the study period

Picciotto et al., JASA 2012

31


3

An application of g-estimation of SNCFTMs:

Alcohol intake and endometrial cancer risk in the Nurses' Health Study



	Protocol of Target Trial	Deviations from the Target Trial in MR study
Eligibility criteria	Women aged 45-48 years; no history of cancer (except for non-melanoma skin cancer) or alcoholism; intact uterus	Additional criteria: women enrolled in Nurses' Health Study; alcohol intake must be measured at baseline
Treatment strategies	(1) Never drink (2) Always $\frac{1}{2}$ drink/day, unless an absolute contraindication for moderate alcohol consumption arises	Can only compare static strategies (e.g., always $\frac{1}{2}$ drink per day, regardless of contraindications for moderate alcohol consumption)
Assignment procedures	Randomly assigned to either strategy at baseline and are aware of the strategy they've been assigned to	Randomly assigned a weighted allele score that is related to their alcohol intake
Follow-up period	Starts at randomization and ends at development of endometrial cancer, incomplete follow-up, or 28 years after baseline (whichever occurs first)	Starts at the time of return of the first questionnaire after all eligibility criteria were met
Outcome	Endometrial cancer	N/A
Causal contrasts	Intention-to-treat effect Per-protocol effect	N/A
Analysis plan	ITT analysis Non-naïve per-protocol analysis	Gene-outcome associations G-estimation of SNCFM via an instrument

33



34

Results



4

Current works in progress &
potential future applications

Current works in progress & potential future applications

Selection bias in Mendelian randomization studies of biomarkers

- MR analyses of biomarkers (e.g., LDL cholesterol) often restrict to non-users of medications that modify levels of these biomarkers (e.g., statins)
- This can introduce selection bias and g-methods are needed to adequately adjust for this bias

More flexible blip functions for SNCFTMs

- Requires estimation of more ψ parameters
- Allow for arbitrary risk curves (e.g., crossing curves)

Per-protocol analyses of trials using SNCFTMs

37

Acknowledgements

- Miguel A. Hernán
- Sonja Swanson
- PhD committee members: Immaculata De Vivo, Peter Kraft, Bernard Rosner
- Collaborators: Elizabeth W. Diemer and CAUSALab
- VA-CAUSAL Methods Core (CSP #2032)



A Center to
Learn What Works



HARVARD
T.H. CHAN

SCHOOL OF PUBLIC HEALTH

38